Further research should also delve into the interactions of ERBB3 isoforms with other molecular pathways in the tumor microenvironment, potentially unveiling new therapeutic targets and deepening our understanding of RCC pathophysiology. This evidence concerns the gene ERBB3 and renal cell carcinoma.